Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.

In diabetes, endothelial nitric oxide synthase (eNOS) produces superoxide anion rather than nitric oxide, referred to as "eNOS uncoupling," which may contribute to endothelial dysfunction, albuminuria, and diabetic nephropathy. Reduced levels of endothelium-derived tetrahydrobiopterin (BH4...

Full description

Bibliographic Details
Main Authors: Kidokoro, K, Satoh, M, Channon, K, Yada, T, Sasaki, T, Kashihara, N
Format: Journal article
Language:English
Published: 2013
_version_ 1797051605558755328
author Kidokoro, K
Satoh, M
Channon, K
Yada, T
Sasaki, T
Kashihara, N
author_facet Kidokoro, K
Satoh, M
Channon, K
Yada, T
Sasaki, T
Kashihara, N
author_sort Kidokoro, K
collection OXFORD
description In diabetes, endothelial nitric oxide synthase (eNOS) produces superoxide anion rather than nitric oxide, referred to as "eNOS uncoupling," which may contribute to endothelial dysfunction, albuminuria, and diabetic nephropathy. Reduced levels of endothelium-derived tetrahydrobiopterin (BH4), an essential cofactor for eNOS, promote eNOS uncoupling. Accelerated degradation of guanosine triphosphate cyclohydrolase I (GTPCH I), the rate-limiting enzyme in BH4 biosynthesis, also occurs in diabetes, suggesting that GTPCH I may have a role in diabetic microvascular disease. Here, we crossed endothelium-dominant GTPCH I transgenic mice with Ins2(+/Akita) diabetic mice and found that endothelial overexpression of GTPCH I led to higher levels of intrarenal BH4 and lower levels of urinary albumin and reactive oxygen species compared with diabetic control mice. Furthermore, GTPCH I overexpression attenuated the hyperpermeability of macromolecules observed in diabetic control mice. In addition, we treated Ins2(+/Akita) mice with metformin, which activates AMP-activated protein kinase (AMPK) and thereby slows the degradation of GTPCH I; despite blood glucose levels that were similar to untreated mice, those treated with metformin had significantly less albuminuria. Similarly, in vitro, treating human glomerular endothelial cells with AMPK activators attenuated glucose-induced reductions in phospho-AMPK, GTPCH I, and coupled eNOS. Taken together, these data suggest that maintenance of endothelial GTPCH I expression and the resulting improvement in BH4 biosynthesis ameliorate diabetic nephropathy.
first_indexed 2024-03-06T18:21:54Z
format Journal article
id oxford-uuid:06952c71-4958-48c2-8d3a-fae7833d1611
institution University of Oxford
language English
last_indexed 2024-03-06T18:21:54Z
publishDate 2013
record_format dspace
spelling oxford-uuid:06952c71-4958-48c2-8d3a-fae7833d16112022-03-26T09:03:19ZMaintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:06952c71-4958-48c2-8d3a-fae7833d1611EnglishSymplectic Elements at Oxford2013Kidokoro, KSatoh, MChannon, KYada, TSasaki, TKashihara, NIn diabetes, endothelial nitric oxide synthase (eNOS) produces superoxide anion rather than nitric oxide, referred to as "eNOS uncoupling," which may contribute to endothelial dysfunction, albuminuria, and diabetic nephropathy. Reduced levels of endothelium-derived tetrahydrobiopterin (BH4), an essential cofactor for eNOS, promote eNOS uncoupling. Accelerated degradation of guanosine triphosphate cyclohydrolase I (GTPCH I), the rate-limiting enzyme in BH4 biosynthesis, also occurs in diabetes, suggesting that GTPCH I may have a role in diabetic microvascular disease. Here, we crossed endothelium-dominant GTPCH I transgenic mice with Ins2(+/Akita) diabetic mice and found that endothelial overexpression of GTPCH I led to higher levels of intrarenal BH4 and lower levels of urinary albumin and reactive oxygen species compared with diabetic control mice. Furthermore, GTPCH I overexpression attenuated the hyperpermeability of macromolecules observed in diabetic control mice. In addition, we treated Ins2(+/Akita) mice with metformin, which activates AMP-activated protein kinase (AMPK) and thereby slows the degradation of GTPCH I; despite blood glucose levels that were similar to untreated mice, those treated with metformin had significantly less albuminuria. Similarly, in vitro, treating human glomerular endothelial cells with AMPK activators attenuated glucose-induced reductions in phospho-AMPK, GTPCH I, and coupled eNOS. Taken together, these data suggest that maintenance of endothelial GTPCH I expression and the resulting improvement in BH4 biosynthesis ameliorate diabetic nephropathy.
spellingShingle Kidokoro, K
Satoh, M
Channon, K
Yada, T
Sasaki, T
Kashihara, N
Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title_full Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title_fullStr Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title_full_unstemmed Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title_short Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
title_sort maintenance of endothelial guanosine triphosphate cyclohydrolase i ameliorates diabetic nephropathy
work_keys_str_mv AT kidokorok maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy
AT satohm maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy
AT channonk maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy
AT yadat maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy
AT sasakit maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy
AT kashiharan maintenanceofendothelialguanosinetriphosphatecyclohydrolaseiamelioratesdiabeticnephropathy